Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
All‐cause mortality · participants with haematological malignancies
BMT showed no clear difference in mortality compared with PBSCT (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · participants with haematological malignancies
BMT showed no clear difference in progress, relapse or death compared with PBSCT (moderate certainty).
1 finding from 1 review
Non relapse or transplant related mortality · participants with haematological malignancies
BMT showed no clear difference in non relapse or transplant related mortality compared with PBSCT (high certainty).
1 finding from 1 review
Chronic GVHD (extensive) · participants with haematological malignancies
BMT probably leads to lower extensive chronic GvHD compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GvHD III to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD III to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Chronic GvHD overall · participants with haematological malignancies
BMT probably leads to lower chronic GvHD overall compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GVHD II to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD II to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review